2021
DOI: 10.1016/j.semarthrit.2021.08.007
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and safety of canakinumab in the treatment of adult-onset Still's disease: A systematic review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
31
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(35 citation statements)
references
References 63 publications
1
31
0
Order By: Relevance
“…As such, a new bDMARD switch was proposed, this time to canakinumab. This interleukin-1β inhibitor has been showing promising results in achieving complete remission in AOSD [19]. We were able to reach this goal with our patient, and complete remission is now sustained for the time being (after one year of follow-up).…”
Section: Discussionsupporting
confidence: 51%
“…As such, a new bDMARD switch was proposed, this time to canakinumab. This interleukin-1β inhibitor has been showing promising results in achieving complete remission in AOSD [19]. We were able to reach this goal with our patient, and complete remission is now sustained for the time being (after one year of follow-up).…”
Section: Discussionsupporting
confidence: 51%
“…Anakinra showed excellent effect for patients with predominantly systemic symptoms and revealed GC-sparing effect 38 . Efficacy and safety of canakinumab are also reported in a systematic review 39 . As IL-1 inhibitors are unavailable in Japan because of the off-label use for AOSD, none of our patients used these agents.…”
Section: Discussionmentioning
confidence: 99%
“…In this context, the CONSIDER trial (a multicenter, randomized, double-blind, placebo-controlled trial), which aimed to employ canakinumab in AOSD subjects with active joint involvement, did not achieve the primary endpoint ( p =0.18) defined as the change in disease activity score (ΔDAS28>1.2). 48 , 49 These results pave the way to new therapeutical strategies, which should be tailored on each patient according to the clinical phenotype presented.…”
Section: Biological Agentsmentioning
confidence: 94%